Advertisement

Preoperative change of modified Glasgow prognostic score after stenting predicts the long-term outcomes of obstructive colorectal cancer

  • Ryuichiro SatoEmail author
  • Masaya Oikawa
  • Tetsuya Kakita
  • Takaho Okada
  • Tomoya Abe
  • Takashi Yazawa
  • Haruyuki Tsuchiya
  • Naoya Akazawa
  • Masaki Sato
  • Tetsuya Ohira
  • Yoshihiro Harada
  • Haruka Okano
  • Kei Ito
  • Noriaki Ohuchi
  • Takashi Tsuchiya
Original Article
  • 15 Downloads

Abstract

Purpose

Inflammation-based markers predict the long-term outcomes of various malignancies. We investigated the relationship between the modified Glasgow prognostic score (mGPS) and the long-term outcomes of obstructive colorectal cancer in patients who underwent self-expandable metallic colonic stent placement and subsequently received curative surgery.

Methods

We retrospectively analyzed 63 consecutive patients with pathological stage II and III obstructive colorectal cancer from 2013 to 2018. The mGPS was calculated before stenting and surgery, and the difference of the scores was defined as the d-mGPS.

Results

All d-mGPS = 2 patients were > 70 years of age (p = 0.01). Postoperative complications were more common in the preoperative mGPS = 2 group (p = 0.02). The postoperative hospital stay was significantly longer in the mGPS = 2 group (p = 0.007). Multivariate analyses revealed that d-mGPS was an independent prognostic factor for overall survival (OS) (hazard ratio [HR] = 9.18, p = 0.004) and cancer-specific survival (HR = 9.98, p = 0.01). Preoperative mGPS = 2 was significantly associated with poor OS (HR = 5.53, p = 0.04).

Conclusion

The results indicated that mGPS might serve as a valuable indicator of the immunonutritional status of preoperative patients, and a preoperative change of the status might affect the long-term outcomes of patients with obstructive colorectal cancer.

Keywords

Modified glasgow prognostic score Obstructive colorectal cancer Retrospective study Self-expandable metallic stent 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest in association with the present study.

Ethical statements

The protocol for this research project was approved by the Ethics Committee of the institution (#2019–0008) and conforms to the provisions of the Declaration of Helsinki.

References

  1. 1.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRefGoogle Scholar
  2. 2.
    Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.CrossRefGoogle Scholar
  3. 3.
    Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140:1537–49.CrossRefGoogle Scholar
  4. 4.
    Dolan RD, McSorley ST, Park JH, Watt DG, Roxburgh CS, Horgan PG, et al. The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores. Br J Cancer. 2018;119:40–51.CrossRefGoogle Scholar
  5. 5.
    Dupré A, Malik HZ. Inflammation and cancer: what a surgical oncologist should know. Eur J Surg Oncol. 2018;44:566–70.CrossRefGoogle Scholar
  6. 6.
    Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep. 2017;7:16717.CrossRefGoogle Scholar
  7. 7.
    Lu X, Guo W, Xu W, Zhang X, Shi Z, Zheng L, et al. Prognostic value of the Glasgow prognostic score in colorectal cancer: a meta-analysis of 9839 patients. Cancer Manag Res. 2018;11:229–49.CrossRefGoogle Scholar
  8. 8.
    McCullough JA, Engledow AH. Treatment options in obstructed left-sided colonic cancer. Clin Oncol (R Coll Radiol). 2010;22:764–70.CrossRefGoogle Scholar
  9. 9.
    Matsuda A, Miyashita M, Matsumoto S, Matsutani T, Sakurazawa N, Takahashi G, et al. Comparison of long-term outcomes of colonic stent as "bridge to surgery" and emergency surgery for malignant large-bowel obstruction: a meta-analysis. Ann Surg Oncol. 2015;22:497–504.CrossRefGoogle Scholar
  10. 10.
    Arezzo A, Passera R, Lo Secco G, Verra M, Bonino MA, Targarona E, et al. Stent as bridge to surgery for left-sided malignant colonic obstruction reduces adverse events and stoma rate compared with emergency surgery: results of a systematic review and meta-analysis of randomized controlled trials. Gastrointest Endosc. 2017;86:416–26.CrossRefGoogle Scholar
  11. 11.
    Allievi N, Ceresoli M, Fugazzola P, Montori G, Coccolini F, Ansaloni L. Endoscopic stenting as bridge to surgery versus emergency resection for left-sided malignant colorectal obstruction: an updated meta-analysis. Int J Surg Oncol. 2017;2017:2863272.Google Scholar
  12. 12.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefGoogle Scholar
  13. 13.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  14. 14.
    Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transpl. 2013;48:452–8.CrossRefGoogle Scholar
  15. 15.
    Frago R, Ramirez E, Millan M, Kreisler E, del Valle E, Biondo S. Current management of acute malignant large bowel obstruction: a systematic review. Am J Surg. 2014;207:127–38.CrossRefGoogle Scholar
  16. 16.
    Gainant A. Emergency management of acute colonic cancer obstruction. J Visc Surg. 2012;149:e3–10.CrossRefGoogle Scholar
  17. 17.
    Dohomoto M. New method-endoscopic implantation of rectal stent in palliative treatment of malignant stenosis. Endosc Dig. 1991;3:1507–12.Google Scholar
  18. 18.
    Gorissen KJ, Tuynman JB, Fryer E, Wang L, Uberoi R, Jones OM, et al. Local recurrence after stenting for obstructing left-sided colonic cancer. Br J Surg. 2013;100:1805–9.CrossRefGoogle Scholar
  19. 19.
    Ceresoli M, Allievi N, Coccolini F, Montori G, Fugazzola P, Pisano M, et al. Long-term oncologic outcomes of stent as a bridge to surgery versus emergency surgery in malignant left side colonic obstructions: a meta-analysis. J Gastrointest Oncol. 2017;8:867–76.CrossRefGoogle Scholar
  20. 20.
    Ribeiro IB, Bernardo WM, Martins BDC, de Moura DTH, Baba ER, Josino IR, et al. Colonic stent versus emergency surgery as treatment of malignant colonic obstruction in the palliative setting: a systematic review and meta-analysis. Endosc Int Open. 2018;6:E558–E56767.CrossRefGoogle Scholar
  21. 21.
    Sato R, Oikawa M, Kakita T, Okada T, Oyama A, Abe T, et al. Comparison of the long-term outcomes of the self-expandable metallic stent and transanal decompression tube for obstructive colorectal cancer. Ann Gastroenterol Surg. 2019;3:209–16.CrossRefGoogle Scholar
  22. 22.
    Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89:1028–30.CrossRefGoogle Scholar
  23. 23.
    McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22:881–6.CrossRefGoogle Scholar
  24. 24.
    Lee YJ, Kim WR, Han J, Han YD, Cho MS, Hur H, et al. Prognostic impact of immunonutritional status changes during preoperative chemoradiation in patients with rectal cancer. Ann Coloproctol. 2016;32:208–14.CrossRefGoogle Scholar
  25. 25.
    Park JH, McMillan DC, Horgan PG, Roxburgh CS. The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. Cancer Treat Rev. 2014;40:68–77.CrossRefGoogle Scholar
  26. 26.
    Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591–601.CrossRefGoogle Scholar
  27. 27.
    Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–50.CrossRefGoogle Scholar
  28. 28.
    Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–12.CrossRefGoogle Scholar
  29. 29.
    Coyle C, Cafferty FH, Rowley S, MacKenzie M, Berkman L, Gupta S, et al. ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials. 2016;51:56–64.CrossRefGoogle Scholar
  30. 30.
    Frouws MA, Reimers MS, Swets M, Bastiaannet E, Prinse B, van Eijk R, et al. The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin use and survival after colon cancer diagnosis. PLoS ONE. 2017;12:e0170775.CrossRefGoogle Scholar
  31. 31.
    Li Y, He X, Ding Y, Chen H, Sun L. Statin uses and mortality in colorectal cancer patients: an updated systematic review and meta-analysis. Cancer Med. 2019.  https://doi.org/10.1002/cam4.2151.Google Scholar
  32. 32.
    Deva S, Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database Syst Rev. 2012;8:CD007814.Google Scholar
  33. 33.
    Buijs N, van Bokhorst-de van der Schueren MA, Langius JA, Leemans CR, Kuik DJ, Vermeulen MA, et al. Perioperative arginine-supplemented nutrition in malnourished patients with head and neck cancer improves long-term survival. Am J Clin Nutr. 2010;92:1151–6.CrossRefGoogle Scholar
  34. 34.
    Xu J, Sun X, Xin Q, Cheng Y, Zhan Z, Zhang J, et al. Effect of immunonutrition on colorectal cancer patients undergoing surgery: a meta-analysis. Int J Colorectal Dis. 2018;33:273–83.CrossRefGoogle Scholar
  35. 35.
    Kanekiyo S, Takeda S, Iida M, Nishiyama M, Kitahara M, Shindo Y, et al. Efficacy of perioperative immunonutrition in esophageal cancer patients undergoing esophagectomy. Nutrition. 2018;59:96–102.CrossRefGoogle Scholar
  36. 36.
    National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: colon cancer. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 17 Jun 2019.
  37. 37.
    Peng J, Zhang R, Zhao Y, Wu X, Chen G, Wan D, et al. Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer. Chin J Cancer. 2017;36:96.CrossRefGoogle Scholar
  38. 38.
    Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host. Ann Surg. 2016;263:326–36.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Ryuichiro Sato
    • 1
    Email author
  • Masaya Oikawa
    • 1
  • Tetsuya Kakita
    • 1
  • Takaho Okada
    • 1
  • Tomoya Abe
    • 1
  • Takashi Yazawa
    • 1
  • Haruyuki Tsuchiya
    • 1
  • Naoya Akazawa
    • 1
  • Masaki Sato
    • 1
  • Tetsuya Ohira
    • 2
  • Yoshihiro Harada
    • 2
  • Haruka Okano
    • 2
  • Kei Ito
    • 2
  • Noriaki Ohuchi
    • 1
  • Takashi Tsuchiya
    • 1
  1. 1.Department of Gastroenterological SurgerySendai City Medical Center Sendai Open HospitalSendaiJapan
  2. 2.Department of GastroenterologySendai City Medical Center Sendai Open HospitalSendaiJapan

Personalised recommendations